Gastrointestinal stromal tumor (GIST)
- Surgery for resectable localized disease
- Imatinib is the key first-line TKI for sensitive KIT/PDGFRA disease
- Mutation testing predicts TKI sensitivity
- Adjuvant imatinib for selected high-risk resected GIST
- Resistance → sequential later-line TKIs
- PDGFRA D842V requires a different targeted strategy
Use at a glance
- Surgery for resectable localized disease
Escalation / refractory disease
- Imatinib is the key first-line TKI for sensitive KIT/PDGFRA disease
- Resistance → sequential later-line TKIs
Practical pearls
- Mutation testing predicts TKI sensitivity
- PDGFRA D842V requires a different targeted strategy
Choosing treatment
- Adjuvant imatinib for selected high-risk resected GIST
Self-check
- What is recommended for Resistance in Gastrointestinal stromal tumor (GIST)?
sequential later-line TKIs.
- What is required when PDGFRA D842V occurs in Gastrointestinal stromal tumor (GIST)?
a different targeted strategy.
Drugs used for this (1)
All clinical uses · Open the interactive console ↗
